Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 418-424

  Swoboda, Stefanie ^a   Lichtenstern, Christoph ^a,c   Ober, Michael Christoff ^a   Taylor, Lenka Alexandra ^d   Störzinger, Dominic ^a   Michel, André ^a   Brobeil, Angelika ^a   Mieth, Markus ^a   Hofer, Stefan ^a   Sonntag, Hans Günther ^b   Hoppe Tichy, Torsten ^a   Weigand, Markus Alexander ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Antifungal agents; Antifungal therapy, practice guidelines; Clinical pharmacist; Pharmaeconomic

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ABDOMINAL SURGERY; ADULT; AGED; ANTIFUNGAL THERAPY; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; ASPERGILLUS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG UTILIZATION; FEMALE; FUSARIUM; HUMAN; IMMUNOCOMPROMISED PATIENT; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MUCOR; MYCOSIS; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; SURGICAL INTENSIVE CARE UNIT;

ANTIFUNGAL AGENTS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; MYCOSES; PHARMACISTS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL ROLE;

EID: 71249123989     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264672     Document Type: Article

References (30)

1. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K: Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606-618.
2. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel- Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-186.
3. Petri MG, Konig J, Moecke HP, Gramm HJ, Barkow H, Kujath P, Dennhart R, Schafer H, Meyer N, Kalmar P, Thulig P, Muller J, Lode H: Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 1997; 23: 317-325. (Pubitemid 27129998)
4. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
5. Kumar A, Group C: The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. Abstract K-2174. Chicago, ICAAC, 2007.
6. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
7. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
8. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA: Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-485.
9. Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857-863.
10. Garnacho-Montero J, Maya-Villar R, Ortiz- Leyba C, Leon C, Varez-Lerma F, Nolla-Salas J, Iruretagoyena JR, Barcenilla F: Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9: R191-R199.
11. Carrillo-Munoz AJ, Quindos G, Del Valle O, Santos P, Giusiano G, Ezkurra PA, Estivill MD, Casals JB: Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets. Chemotherapy 2008; 54: 38-42.
12. Lichtenstern C, Geiss HK, Boettiger BW, Weigand MA: Antimykotische Therapie in der Intensivmedizin. Intensivmed 2007; 3: 21-37.
13. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F, Vogelaers D: Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10:R31.
14. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
15. Playford EG, Webster AC, Sorell TC, Craig JC: Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004;CD004291.
16. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
17. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J: Guidelines for the selection of anti-infective agents for complicated intraabdominal infections. Clin Infect Dis 2003; 37: 997-1005.
18. Blot S, Vandewoude K: Management of invasive candidiasis in critically ill patients. Drugs 2004; 64: 2159-2175.
19. Spellberg BJ, Filler SG, Edwards JE Jr: Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
20. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del BR, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
21. Martin J, Bause H, Franck M, Geldner G, Gerlach H, Janssens U, Kuckelt W, Kuhlen R, Max M, Meier-Hellmann A, Muhl E, Putensen C, Ragaller M, Reinhart K, Schleppers A, Specht M, Waydhas C, Wegermann P, Weigand MA, Wilhelm W, Spies C: Implementation of evidence-based treatments in the daily intensive medical care routine - management of changes in intensive care. Anaesth Intensivmed 2007; 6:48-53.
22. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
23. Lichtenstern C, Schmidt J, Knaebel HP, Martin E, Buchler MW, Weigand MA: Postoperative bacterial/fungal infections: a challenging problem in critically ill patients after abdominal surgery. Dig Surg 2007; 24: 1-11.
24. Allerberger F, Lechner A, Wechsler-Fordos A, Gareis R: Optimization of antibiotic use in hospitals - antimicrobial stewardship and the EU project ABS international. Chemotherapy 2008; 54: 260-267.
25. Meyer E, Buttler J, Schneider C, Strehl E, Schroeren-Boersch B, Gastmeier P, Ruden H, Zentner J, Daschner FD, Schwab F: Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced. J Antimicrob Chemother 2007; 59: 1148-1154.
26. Marshall J, Finn CA, Theodore AC: Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med 2008; 36: 427-433.
27. Kane SL, Weber RJ, Dasta JF: The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med 2003; 29: 691-698.
28. Leape LL, Cullen DJ, Clapp MD: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267-270.
29. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
30. Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC: Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 2006; 32: 599-603.